In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

Bas D. Koster; Tamarah D. de Jong; Mari F.C.M. van den Hout; Berbel J.R. Sluijter; Ronald J.C.L.M. Vuylsteke; Barbara G. Molenkamp; Saskia Vosslamber; M. Petrousjka van den Tol; Alfons J.M. van den Eertwegh; Tanja D. de Gruijl

Journal ArticleOPEN ACCESS

In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

Koster B
de Jong T
van den Hout M
et al.

OncoImmunology (2020) 9(1)

DOI: 10.1080/2162402X.2019.1708066

7Citations

21Readers

Abstract

Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences.

Author supplied keywords

CpG
GM-CSF
dendritic cells
melanoma
sentinel lymph node

Cite

CITATION STYLE

APA

Koster, B. D., de Jong, T. D., van den Hout, M. F. C. M., Sluijter, B. J. R., Vuylsteke, R. J. C. L. M., Molenkamp, B. G., … de Gruijl, T. D. (2020). In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma. OncoImmunology, 9(1). https://doi.org/10.1080/2162402X.2019.1708066

In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma

Abstract

Author supplied keywords

Cite

Register to see more suggestions